معرفی
Dr David Dickens is a Lecturer and Principal Investigator in the Department of Pharmacology and Therapeutics at the University of Liverpool. His research focuses on blood-brain barrier (BBB) transporters and drug delivery mechanisms for CNS treatments.
His work investigates transporter pharmacology at the BBB interface, molecular properties of transport mechanisms, and pharmacogenetic approaches for personalized medicine. Current projects utilize iPSC-derived human cell models to study disease-specific BBB effects in brain cancer and inter-patient drug response variability.
Recent publications (2023-2025) emphasize BBB transporter biology, particularly LAT1 and P-glycoprotein roles in CNS drug delivery for neurological disorders, with significant focus on AV-101 and clozapine transport mechanisms.
Research funding includes:
- 2024-25 Bench Fees for Yahya Mohammed A Alzahrani (Royal Embassy of Saudi Arabia)
- 2017-2023 AV-101 transporter study (VistaGen Therapeutics)
- 2018-2021 Bench Fees for Wedad Alhassan K Mawkili (Royal Embassy of Saudi Arabia)
- 2017-2018 Crystallographic detector development (BBSRC)
- 2010-2014 Antiepileptic drug transport study (Epilepsy Research Institute)
The Dickens Lab pioneers advanced iPSC-based BBB models for transporter research, collaborating internationally as demonstrated by the 2025 Lancet Neurology review on BBB therapeutic strategies.
